Ezetimibe/rosuvastatin - Ildong Pharmaceutical

Drug Profile

Ezetimibe/rosuvastatin - Ildong Pharmaceutical

Alternative Names: Rosuvastatin/ezetimibe - Ildong Pharmaceutical

Latest Information Update: 20 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ildong Pharmaceutical
  • Class Antihyperlipidaemics; Azetidines; Fluorobenzenes; Propanols; Pyrimidines; Small molecules; Sulfonamides
  • Mechanism of Action Cholesterol absorption inhibitors; HMG-CoA reductase inhibitors; NPC1L1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Hypercholesterolaemia

Most Recent Events

  • 01 Feb 2017 IlDong Pharmaceutical completes the phase III I-ROSETTE trial for Hypercholesterolaemia (In adults, In the elderly) in South Korea (PO) (NCT02749994)
  • 06 May 2016 Chemical structure information added
  • 01 Apr 2016 IlDong Pharmaceutical initiates the phase III I-ROSETTE trial for Hypercholesterolaemia (In adults, In the elderly) in South Korea (PO) (NCT02749994)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top